fda bpc-157 not approved human use warning FDA's Overreach on Compounded Peptides FDA panel narrowly backs unapproved

What seems logical based on mechanism of action may not translate directly to additive or synergistic clinical effects

The peptides degrade in gastric acid and interstitial proteases before reaching systemic circulation

Preclinical evidence from the Sikiric lab and collaborators describes protective effects against ethanol-induced gastric lesions, NSAID-induced enteropathy, and ileoileal anastomotic disruption in rat models, with the latter studied under the Pliva clinical-development code PL-14736 (Tkalcevi et al., 2007

Neuroprotective & Recovery Support May protect brain cells from oxidative stress and excitotoxicity

However, human studies have not yet examined this mechanism in detail